A synthesis of cost-utility analysis literature in infectious diseaseQuantitative Health Sciences Publications and Presentations
UMMS AffiliationDepartment of Quantitative Health Sciences
SubjectsAnti-Bacterial Agents; Communicable Diseases; Cost-Benefit Analysis; Humans; Immunization; Periodicals as Topic; Publishing; *Quality-Adjusted Life Years; Time Factors
AbstractThe purpose of this review is to understand infectious disease-related cost-utility analyses by describing published analyses, examining growth and quality trends over time, examining factors related to quality, and summarising standardised results. 122 cost-utility analyses and 352 cost-utility ratios were identified. Pharmaceutical interventions were most common (47.5%); three author groups accounted for 42.8% of pharmaceutical ratios. High-volume journals (three or more published cost-utility analyses) published higher quality analyses than low-volume journals (p<0.001). Use of probabilistic sensitivity analysis and discounting at 3% were more frequently found in the years after the US Public Health Service Panel on Cost-Effectiveness in Health and Medicine recommendations (p<0.01). Median ratios varied from US13,500 dollars/quality-adjusted life year (QALY) for immunisations to US810,000 dollars/QALY for blood safety. Publication of infectious disease cost-utility analyses is increasing. The results of cost-utility analyses have important implications for the development of clinical guidelines and resource allocation decisions. More trained investigators and better peer-review processes are needed.
Rights and PermissionsCitation: Lancet Infect Dis. 2005 Jun;5(6):383-91. Link to article on publisher's site
Related ResourcesLink to Article in PubMed
Citation InformationPatricia W. Stone, Bruce R. Schackman, Christopher P. Neukermans, Natalia V. Olchanski, et al.. "A synthesis of cost-utility analysis literature in infectious disease" Vol. 5 Iss. 6 (2005) ISSN: 1473-3099 (Linking)
Available at: http://works.bepress.com/allison_rosen/44/